Article

Zealand Pharma has partnered with DCAI to leverage the Gefion AI supercomputer to enhance drug discovery for metabolic diseases, aiming to support its 'Metabolic Frontier 2030' strategy with multiple product launches and clinical programs. This collaboration will integrate advanced protein-peptide simulations to expedite the development process.

Despite recent stock declines, analysts maintain a positive outlook, with an average price target of 745.93 DKK, as CEO Adam Steensberg prepares to present updates at the upcoming J.P. Morgan Healthcare Conference.